Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0392
Source ID: NCT05742724
Associated Drug: Tetrahydrocannabinol-Cannabidiol Combination
Title: The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and Cannabidiol
Acronym: POT-GFR-PK
Status: ACTIVE_NOT_RECRUITING
Study Results: NO
Results:
Conditions: Cannabis|Chronic Kidney Diseases|Dialysis
Interventions: DRUG: Tetrahydrocannabinol-Cannabidiol Combination
Outcome Measures: Primary: Tetrahydrocannabinol and its metabolites maximum concentration (Cmax), Maximum concentration (Cmax), 48 hours|Tetrahydrocannabinol and its metabolites time to Cmax, Time to Cmax, 48 hours|Tetrahydrocannabinol and its metabolites last detection time, Last detection time, 48 hours|Tetrahydrocannabinol and its metabolites area under the curve, Area under the curve, 48 hours|Tetrahydrocannabinol and its metabolites renal clearance, Renal clearance, 48 hours|Tetrahydrocannabinol and its metabolites dialytic clearance, Dialytic clearance, 48 hours|Cannabidiol and its metabolites maximum concentration (Cmax), Maximum concentration (Cmax), 48 hours|Cannabidiol and its metabolites time to Cmax, Time to Cmax, 48 hours|Cannabidiol and its metabolites last detection time, Last detection time, 48 hours|Cannabidiol and its metabolites area under the curve, Area under the curve, 48 hours|Cannabidiol and its metabolites renal clearance, Renal clearance, 48 hours|Cannabidiol and its metabolites dialytic clearance, Dialytic clearance, 48 hours|Other cannabinoids and their metabolites maximum concentration (Cmax), Maximum concentration (Cmax), 48 hours|Other cannabinoids and their metabolites time to Cmax, Time to Cmax, 48 hours|Other cannabinoids and their metabolites last detection time, Last detection time, 48 hours|Other cannabinoids and their metabolites area under the curve, Area under the curve, 48 hours|Other cannabinoids and their metabolites renal clearance, Renal clearance, 48 hours|Other cannabinoids and their metabolites dialytic clearance, Dialytic clearance, 48 hours | Secondary: Adverse events, Weakness, fatigue, pain, falls, abnormal coordination, numbness or tingling, sedation, sleepiness, tremor, confusion, disorientation, dissociation, abnormal speech, muscle spasms, nausea, vomiting, diarrhea, altered mood, depression, euphoric mood, hallucinations, blurred vision, dizziness, imbalance, palpitations, hypotension, syncope, urinary tract infection, allergic reactions, shortness of breath, lung infection, fever, sweatiness, headache, 48 hours|Blood pressure, Systolic and diastolic blood pressure in mmHg, 48 hours|Heart rate, Heart rate in beats per minute, 48 hours
Sponsor/Collaborators: Sponsor: McMaster University | Collaborators: Center for Medicinal Cannabis Research
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE1
Enrollment: 24
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER
Start Date: 2024-01-11
Completion Date: 2025-03-01
Results First Posted:
Last Update Posted: 2024-11-20
Locations: St. Joseph's Healthcare Hamilton, Hamilton, Ontario, L8S 4A6, Canada
URL: https://clinicaltrials.gov/show/NCT05742724